The observed increase in AML cells harboring a FLT3-ITD mutation following treatment may indicate a clonal selection in which a small pool of FLT3-ITD cells are able to selectively withstand treatment and repopulate the marrow. This evidence concerns the gene FLT3 and acute myeloid leukemia.